drugset / Trial / NCT07250269
Study of GC012F, CAR-T Therapy Targeting CD19 and BCMA in Chinese Participants With Relapsed or Refractory AL Amyloidosis
Phase 1
Recruiting
9 enrolled
Gracell Biotechnologies (Shanghai) Co., Ltd.
Suzhou Gracell Biotechnologies Co., Ltd. · collab
Non-randomizedSingle-groupOpen-labelTreatment
Summary
This is a Phase 1b open-label, multicenter, non-randomized study of GC012F, a CD19/BCMA dual CAR T cell therapy, in adult participants with relapsed/refractory AL amyloidosis.
Timeline
- Start
- 2025-10-29
- Primary completion
- 2028-11-24
- Completion
- 2028-11-24
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | GC012F | Cell therapy | — | — |